Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FDQDW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,715
Award facts
- Contract value 100% obligated
- $22,714.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a firm fixed-price delivery order valued at $22,714.80 to DMS Pharmaceutical Group Inc. for NUCALA 100 MG/ML auto-injector supplies, with an ultimate completion date of October 27, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which represents a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
NUCALA (mepolizumab) is a biologic immunosuppressant commonly used in specialty pharmaceutical applications. As a regional prime vendor contractor under the PPV-G GEN V program, DMS Pharmaceutical Group maintains authorization to supply a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support recurring medical supply needs across military healthcare operations. The company's established performance on numerous delivery orders throughout October 2025 demonstrates its operational capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, with the broader IDC ceiling value of $499,999,999 extending through December 31, 2036.
Quick answers
Who was awarded contract SPE2DB26FDQDW?
SPE2DB26FDQDW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DB26FDQDW worth?
The government has obligated $22,715 on SPE2DB26FDQDW.
Is contract SPE2DB26FDQDW an order under another contract?
Yes. SPE2DB26FDQDW is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDW competed?
The extent of competition for SPE2DB26FDQDW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award